EIF4G1 and cancer: Torkinib (pp242) has the ability to inhibit mTOR or deplete the cell of eIF4E or eIF4G1, therefore inhibiting the production of SGs in cancer cells. As a result, the p21 anti-apoptotic pathway is blocked, and cancer cells become susceptible to chemotherapy and, eventually, death.